Microbot Medical completes final PIO exercise closing, raising $29.2M initial gross proceeds

Microbot Medical Inc.

Three closings: $25.2M (first), $1.2M (second), $2.8M (third) – total $29.2M gross proceeds before fees.
New series J preferred investment options issued; exercise price $4.50, exercisable after 6 months, 2-year term.
Potential additional ~$63M if series J options fully exercised on a cash basis (no guarantee).
Net proceeds to fund development/commercialization of LIBERTY Robotic System and for working capital.
H.C. Wainwright & Co. served as exclusive placement agent for the offering.

item 1.01 item 3.02 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-25-017212
form_type: 8-K
ticker: MBOT
cik: 0000883975
company_name: Microbot Medical Inc.
filed_at: 2025-10-07T23:59:59+00:00
discovered_at: 2026-05-14T18:02:42.469429+00:00
generated_at: 2026-05-17T04:31:56.748817+00:00
sec_items: ["1.01", "3.02", "8.01", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-25-017212
json_url: https://secwatch.observer/filing/0001493152-25-017212.json
markdown_url: https://secwatch.observer/filing/0001493152-25-017212.md
text_url: https://secwatch.observer/filing/0001493152-25-017212.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/883975/000149315225017212/0001493152-25-017212-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/883975/000149315225017212/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001493152-25-017212

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.